Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanwujiaowan is a Traditional Chinese Medicine (TCM) formulation traditionally used for the treatment of cold-dampness Bi-syndrome, which encompasses conditions such as rheumatoid arthritis, osteoarthritis, and chronic joint pain. The formula is composed of three primary herbal ingredients: *Aconitum carmichaelii* (Chuanwu), *Aconitum kusnezoffii* (Caowu), and *Zanthoxylum bungeanum* (Huajiao). Its therapeutic efficacy is derived from the synergistic action of its chemical constituents, most notably aconitine-type alkaloids and alkylamides such as sanshools. Aconitine acts as a potent modulator of voltage-gated sodium channels, prolonging their open state to exert analgesic effects, while sanshools interact with TRPV1 and KCNK potassium channels to produce a characteristic numbing sensation and further pain relief. Due to the inherent toxicity of *Aconitum* species, the herbs are typically processed (paozhi) to reduce alkaloid concentrations before formulation. It is manufactured by several traditional pharmaceutical companies in China and is recognized for its potent anti-inflammatory and antinociceptive properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sanwujiaowan.